MedTrace Logo

Coenzyme Q10 in Huntington's Disease (HD)

NCT00608881 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 609

Last updated 2016-03-30

Study results available
· View outcomes & findings →

Summary

The goals of this trial are to determine if coenzyme Q10 is effective in slowing the worsening symptoms of Huntington's disease and to learn about the safety and acceptability of long-term coenzyme Q10 use by determining its effects on people with Huntington's disease.

Conditions

Interventions

DRUG

coenzyme Q10

4 - 300 mg CoQ chewable wafers taken orally twice a day

OTHER

placebo

an inactive substance

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • University of Rochester

    collaborator OTHER

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Merit Cudkowicz, MD MSc · Massachusetts General Hospital

  • Michael McDermott, PhD · University of Rochester, Biostatistics

  • Karl Kieburtz, MD MPH · Director, Clinical Trials Coordination Center, University of Rochester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2014-11-30
Completion
2015-05-31

Countries

  • United States
  • Australia
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00608881 on ClinicalTrials.gov